Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure
- PMID: 27654854
- DOI: 10.1016/j.jacc.2016.09.004
Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure
Abstract
Background: The oral vasopressin-2 receptor antagonist tolvaptan causes aquaresis in patients with volume overload, potentially facilitating decongestion and improving the clinical course of patients with acute heart failure (AHF).
Objectives: The TACTICS-HF (Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure) study was conducted to address the acute use of tolvaptan to improve congestion in AHF.
Methods: The TACTICS-HF study randomized patients (n = 257) within 24 h of AHF presentation in a prospective, double blind, placebo-controlled trial. Patients were eligible regardless of ejection fraction, and were randomized to either 30 mg of tolvaptan or placebo given at 0, 24, and 48 h, with a fixed-dose furosemide regimen as background therapy. The primary endpoint was the proportion of patients considered responders at 24 h. Secondary endpoints included symptom improvement, changes in renal function, and clinical events.
Results: Dyspnea relief by Likert scale was similar between groups at 8 h (25% moderately or markedly improved with tolvaptan vs. 28% placebo; p = 0.59) and at 24 h (50% tolvaptan vs. 47% placebo; p = 0.80). Need for rescue therapy was also similar at 24 h (21% tolvaptan, 18% placebo; p = 0.57). The proportion defined as responders at 24 h (primary study endpoint) was 16% for tolvaptan and 20% for placebo (p = 0.32). Tolvaptan resulted in greater weight loss and net fluid loss compared with placebo, but tolvaptan-treated patients were more likely to experience worsening renal function during treatment. There were no differences in in-hospital or post-discharge clinical outcomes.
Conclusions: In patients hospitalized with AHF, dyspnea, and congestion, the addition of tolvaptan to a standardized furosemide regimen did not improve the number of responders at 24 h, despite greater weight loss and fluid loss. (Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure [TACTICS-HF]; NCT01644331).
Keywords: acute heart failure; decongestion; outcomes; strategies; volume overload.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Tolvaptan in Acute Heart Failure: Time to Move On.J Am Coll Cardiol. 2017 Mar 21;69(11):1407-1408. doi: 10.1016/j.jacc.2016.09.005. Epub 2016 Sep 18. J Am Coll Cardiol. 2017. PMID: 27654853 No abstract available.
-
Heart failure: No early benefits of adjunct therapy with tolvaptan for acute heart failure.Nat Rev Cardiol. 2017 May;14(5):256. doi: 10.1038/nrcardio.2017.46. Epub 2017 Mar 31. Nat Rev Cardiol. 2017. PMID: 28361975 No abstract available.
Similar articles
-
Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.J Am Coll Cardiol. 2017 Mar 21;69(11):1409-1419. doi: 10.1016/j.jacc.2016.12.035. J Am Coll Cardiol. 2017. PMID: 28302292 Clinical Trial.
-
Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.Circ Heart Fail. 2015 Sep;8(5):997-1005. doi: 10.1161/CIRCHEARTFAILURE.115.002259. Circ Heart Fail. 2015. PMID: 26374918 Review.
-
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.JAMA. 2007 Mar 28;297(12):1332-43. doi: 10.1001/jama.297.12.1332. Epub 2007 Mar 25. JAMA. 2007. PMID: 17384438 Clinical Trial.
-
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.JAMA. 2004 Apr 28;291(16):1963-71. doi: 10.1001/jama.291.16.1963. JAMA. 2004. PMID: 15113814 Clinical Trial.
-
Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.BMC Cardiovasc Disord. 2017 Jun 20;17(1):164. doi: 10.1186/s12872-017-0598-y. BMC Cardiovasc Disord. 2017. PMID: 28633650 Free PMC article. Review.
Cited by
-
Association of Early Tolvaptan Treatment and Length of In Hospital Stay in Elderly Patients with Acute Decompensated Heart Failure.JMA J. 2024 Oct 15;7(4):564-570. doi: 10.31662/jmaj.2024-0050. Epub 2024 Sep 20. JMA J. 2024. PMID: 39513060 Free PMC article.
-
The Effect of Tolvaptan on Metabolism and Electrolyte Homeostasis in Patients with Heart Failure: A Systematic Review and Meta-Analysis.Rev Cardiovasc Med. 2024 Sep 19;25(9):334. doi: 10.31083/j.rcm2509334. eCollection 2024 Sep. Rev Cardiovasc Med. 2024. PMID: 39355601 Free PMC article.
-
Cardiorenal syndrome: evolving concepts and pediatric knowledge gaps.Pediatr Nephrol. 2024 Sep 27. doi: 10.1007/s00467-024-06517-z. Online ahead of print. Pediatr Nephrol. 2024. PMID: 39331078 Review.
-
From Hospital to Home: Evidence-Based Care for Worsening Heart Failure.JACC Adv. 2024 Jul 31;3(9):101131. doi: 10.1016/j.jacadv.2024.101131. eCollection 2024 Sep. JACC Adv. 2024. PMID: 39184855 Free PMC article. Review.
-
Prognostic effect of a vasopressin V2 receptor antagonist in acute congestive heart failure patients with hypoperfusion, the wet-cold pattern.Eur J Clin Pharmacol. 2024 Nov;80(11):1795-1805. doi: 10.1007/s00228-024-03745-y. Epub 2024 Aug 21. Eur J Clin Pharmacol. 2024. PMID: 39168874
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
